ArticleAdvances in therapy2026
The Impact of the COVID-19 Pandemic on Adherence and Persistence to Glaucoma Therapy: A Retrospective Italian Cohort Study.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionThe COVID-19 pandemic disrupted routine healthcare delivery worldwide. For patients with chronic conditions requiring lifelong therapy, such as glaucoma, this disruption threatened continuity of care. We aimed to quantify the pandemic's impact on medication adherence and persistence using a large Italian administrative database.
methodsWe conducted a retrospective cohort study using healthcare databases from Lombardy, Italy. Established patients with glaucoma (defined as ≥ 6 dispensations of ATC S01E medications with a glaucoma diagnosis) were identified in two time periods: 2017 (2018 Cohort, followed from March 2018 before the pandemic) and 2019 (2020 Cohort, followed from March 2020 at pandemic onset). Newly diagnosed patients had no glaucoma therapy in the preceding year. For the primary persistence analysis, follow-up was restricted to 24 months to avoid contamination of the 2018 cohort by pandemic exposure. Persistence was defined as continuous prescription refills allowing a 90-day grace period. Adherence was measured using the Medication Possession Ratio (MPR), with ≥ 80% defined as adherent. We used Cox proportional hazards models and chi-square tests for comparisons.
resultsAmong 111,373 established patients, the risk of discontinuation was significantly higher during the pandemic (adjusted HR 1.17, 95% CI 1.15-1.18; p < 0.001). Absolute persistence rates at 12 months were 89.1% (2018 cohort) vs. 86.7% (2020 cohort); at 24 months, 72.4% vs. 68.9%. This finding was consistent in newly diagnosed-only sensitivity analyses (aHR 1.13, 95% CI 1.08-1.18). Among newly diagnosed patients, adherence was lower in the 2020 cohort (65.1% vs. 68.6%, p < 0.001). New therapy initiations declined by 37% in 2020 (1.0 per thousand at-risk population) compared to 2018 (1.6 per thousand).
conclusionsThe pandemic was associated with significant disruptions to glaucoma therapy, including increased discontinuation among established patients and a marked reduction in new treatment initiations. These findings highlight the vulnerability of daily drop-based regimens to healthcare system disruptions. More resilient therapeutic approaches merit further consideration.
Indexed as
Identifiers
42461574What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.